First trial of Norwegian T-cell corona vaccine

Vaccination - vaccinatedPhoto: Torstein Bøe / NTB

A first subject has received a dose of the Norwegian Nykode Therapeutics’ T-cell vaccine candidate against the coronavirus in a clinical study.

In total, the company has developed three vaccine candidates against the coronavirus. The T-cell and RBD vaccine candidates are now going through clinical studies, Dagens Medisin writes.

The studies are carried out at Oslo University Hospital and Haukeland University Hospital. The purpose of developing a vaccine based on T cells is to provide a broader immune response against the coronavirus, which also works against new variants. In addition, it should be easier to produce than the Pfizer and Moderna mRNA vaccines, as they use DNA plasmid, which is normally an intermediate step in the production of mRNA vaccines.

Nykode Therapeutics has great faith in the vaccine candidate, which is still some distance away from approval and general use. CEO Michael Engsig says preclinical studies have shown that the vaccine is well tolerated and provides good cross-protection.

“What we are trying to achieve with this T-cell vaccine is to provide longer protection, better cross-protection against new variants, and a larger therapeutic window when it comes to vaccination. It is also a vaccine candidate that is easier to produce, distribute and administer, which is necessary to get vaccines to those parts of the world where it is challenging to get mRNA vaccines,” he told Dagens Medisin.

Source: © NTB Scanpix / #Norway Today / #NorwayTodayNews

Do you have a news tip for Norway Today? We want to hear it. Get in touch at [email protected]

Be the first to comment on "First trial of Norwegian T-cell corona vaccine"

Leave a comment

Your email address will not be published.


*